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ABSTRACT
Background: Probiotic administration may be a useful method for preventing allergies in infants; however,
there have been controversial results about the efficacy. We investigated the effects of bifidobacterial supple-
mentation on the risk of developing allergic diseases in the Japanese population.
Methods: In an open trial, we gave Bifidobacterium breve M-16V and Bifidobacterium longum BB536 prena-
tally to 130 mothers beginning 1 month prior to delivery and postnatally to their infants for 6 months. Another 36
mother-infant pairs served as controls and did not receive the bifidobacterial supplementation. Development of
allergic symptoms in the infants was assessed at 4, 10 and 18 months of age. Fecal samples were collected
from the mothers and infants.
Results: The risk of developing eczemaatopic dermatitis (AD) during the first 18 months of life was signifi-
cantly reduced in infants in the probiotic group (OR: 0.231 [95% CI: 0.084-0.628] and 0.304 [0.105-0.892] at 10
and 18 months of age, respectively). Pyrosequencing analyses indicated an altered composition of the fecal mi-
crobiota at 4 months for infants who developed eczemaAD at 4 and 10 months of age. The proportion of Pro-
teobacteria was significantly lower (P = 0.007) in mothers at the time of delivery who received the supplementa-
tion when compared with the control group and was positively correlated (r = 0.283, P = 0.024) with that of in-
fants at 4 months of age. No adverse effects were related to the use of probiotics.
Conclusions: These data suggest that the prenatal and postnatal supplementation of bifidobacteria is effec-
tive in primary preventing allergic diseases. Some limited changes in the composition of fecal microbiota by the
bifidobacterial supplementation were observed.
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INTRODUCTION
The prevalence of allergic diseases, such as eczema,
allergic rhinitis, and asthma, has rapidly increased
worldwide over the past several decades, particularly
in industrialized countries. One explanation for the
prevalence of allergies is the “hygiene hypothesis”,
which postulates that decreased exposure to im-
munostimulating pathogens in early childhood in-
creases the prevalence of allergic diseases.1 Several
studies have suggested an association between the
composition of the intestinal microbiota and the de-
velopment of allergies.2 Increasing numbers of clini-
cal trials have focused on the use of Lactobacillus or
Bifidobacterium strains (or a mixture of these) early
in life for the prevention of atopic diseases; however,
these trials have reported controversial results re-
garding the efficacy of such treatments.3-6 A meta-
analysis based on 14 studies demonstrated that probi-
otic use decreased the incidence of atopic dermatitis
[relative risk = 0.79, 95% confidence interval (CI):
0.71-0.88], providing evidence in support of a moder-
ate role of probiotics in the prevention of atopic der-
matitis and IgE-associated atopic dermatitis in in-
fants.7 Similarly, a meta-analysis by Elazab et al.8 has
suggested that prenatal andor early-life probiotic ad-
ministration reduces the risk of atopic sensitization
and decreases total IgE levels in children but might
not reduce the risk of asthma or wheezing. They
found that administration of L. acidophilus was associ-
ated with an increased risk of atopic sensitization (P =
0.002) when compared with other strains, indicating
the importance of probiotic strain selection.8 Hetero-
geneous factors involved in each clinical trial, such as
the inclusion criteria for the study subjects, the tim-
ing of the probiotic intervention, the mode of admini-
stration, and the probiotic strains used, might con-
tribute to the different outcomes observed between
studies.
In the present study, we administered a combina-
tion of Bifidobacterium strains, Bifidobacterium lon-
gum BB536 and B. breve M-16V, prenatally to moth-
ers during their last month (mo) of pregnancy and
postnatally to their infants for 6 mo and assessed the
effects of the bacteria on the prevention of atopic dis-
eases in infants. An analysis of the fecal microbiota
was performed to gain insight into the association of
the microbiota with allergy development and probi-
otic ingestion. We employed a mixture of two Bifido-
bacterium strains, B. longum BB536 and B. breve M-
16V, to attempt to achieve a wider spectrum of effi-
cacy. These strains were originally isolated from
healthy infants, and each strain has shown a high po-
tential for anti-allergic effects in animals and clinical
trials. B. longum BB536 alleviates the symptoms of
certain allergic diseases, such as Japanese cedar polli-
nosis.9-11 B. breve M-16V reduces allergic sensitiza-
tion in ovalbumin-sensitized mice, alleviates IgE-
mediated allergic symptoms, and prevents asthma-
related symptoms in infants.12-14 The study was per-
formed as part of the Kinokunimoritsukuri project,
which is supported by Wakayama Prefecture, Japan,
an area abundant with Japanese cedar and known to
have a high prevalence of allergies to pollen. Overall,
the project aimed to investigate the prevalence of al-
lergic diseases, including food allergy, atopic dermati-
tis (AD), allergic asthma, allergic rhinitis, allergic
conjunctivitis, and Japanese cedar pollen allergy in
Wakayama Prefecture and to develop a strategy for
allergy care in the future.
METHODS
STUDY DESIGN AND PARTICIPANTS
This open-trial study was conducted in a single center
(Hidaka General Hospital) in Wakayama, Japan. The
trial flow is presented in Figure 1. Subject recruit-
ment occurred between September 2008 and Decem-
ber 2010. Information about the study was distributed
to pregnant women in the hospital. All families who
were interested in participating contacted the re-
search nurse during the recruitment period and were
assessed for eligibility. Pregnant women with severe
hepatic dysfunction, renal dysfunction, cardiovascular
disorders, respiratory dysfunction, endocrine disor-
ders, or metabolic dysfunction were excluded from
the study. Other exclusion criteria included habitual
ingestion of probiotic supplements. A total of 166
pregnant women were enrolled; 130 were assigned to
the probiotic group, and 36 were assigned to the con-
trol group based on the willingness of the partici-
pants. The baseline characteristics of these partici-
pants in the probiotic and control groups are shown
in Table 1. All of the participants provided written in-
formed consent. All of the study protocols were ap-
proved and controlled by the Local Ethics Committee
of Hidaka General Hospital and the Local Ethics
Committee of the NPO (Nonprofit Organization)
Japan Health Promotion Supporting Network, Waka-
yama, Japan.
SAMPLE INTAKE
Pregnant women in the probiotic group received
daily two sachets of bifidobacterial powder (approxi-
mately 1 g per sachet, each containing approximately
5 × 109 colony-forming units of B. longum BB536
[ATCC BAA-999] and B. breve M-16V [LMG 23729])
beginning at approximately 4 wk before the date of
expected delivery. The participants were advised to
ingest the bifidobacterial powder by drinking it with
milk or water. After delivery, the infants were given
one sachet of the same bifidobacterial powder to be
consumed daily in breast milk or water for breast-
feeding infants or in formula or water for formula-
feeding infants beginning approximately 1 wk after
birth and continuing for 6 mo. The control group did
not receive the probiotic supplementation. The moth-
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Fig.　1　Study fl ow.
Enrollment
Allocation
Follow-up
Analysis
Excluded (n = 26)
(did not meet inclusion criteria)
192  mothers screened
Control group (n = 36) Probiotic group (n = 130)
Discontinued intervention (n =1)
• 1 retired after 4 months of age
Failed to participate in examination
• 3 at 4 months of age
• 4 at 10 months of age
• 4 at 18 months of age
Lost to follow-up (n = 3)
• 1 lost to follow-up after 4 months of age
• 2 lost to follow-up after 10 months of age
Discontinued intervention (n = 13)
• 6 retired after hospital discharge
• 4 retired after 4 months of age
• 2 family moved after 4 months of age
• 1 retired after 10 months of age
Failed to participate in examination
• 11 at 4 months of age
• 14 at 10 months of age
• 18 at 10 months of age
Control group
• 4 months of age (n = 32)
• 10 months of age (n = 31)
• 18 months of age (n = 31)
Excluded from analyses (n = 0)
Bifidobacterium group
• 4 months of age (n = 112)
• 10 months of age (n = 101)
• 18 months of age (n = 94)
Excluded from analyses (n = 2)
• 2 infants did not ingest
Table　1　Background characteristics of mother-infant pairs
Control group 
(n = 36)
Probiotic group
(n = 122) P
†
Maternal
Age (year), mean (range) 29.7 (21-38) 30.9 (22-41) 0.147
Food allergy (%) 8.8 15.3 0.337
Eczema/atopic dermatitis (%) 11.8 31.5 0.023
Allergic asthma (%) 0.0 9.8 0.057
Allergic rhinitis (%) 30.3 40.9 0.272
Allergic conjunctivitis (%) 6.1 16.4 0.134
With at least one allergy (%)‡ 36.1 55.7 0.038
Smoking (%) 9.1 5.4 0.443
Habitual ingestion of fermented milk during pregnancy (%) 90.9 89.0 0.753
Family
Family history of allergy (%)§ 68.6 81.1 0.111
Pets, ratio (%) 16.7 22.1 0.478
Smokers in family (%) 55.6 47.5 0.398
Infant
Boy, ratio (%) 50.0 49.6 0.652
Older siblings, ratio (%) 69.4 61.7 0.533
Cesarean section, ratio (%) 5.5 16.4 0.137
Birth weight, ratio (% of <2500 g) 0.0 4.1 0.215
Primarily breast-fed, ratio (%) 56.1 47.9 0.699
†Groups were compared using Student’s t-test for continuous variables and Fisher’s exact test for categorical variables.
‡Having at least one of the above allergic disorders.
§Family history including grand fathers, grand mothers, fathers, mothers and siblings of infants.
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ers and infants were advised to avoid ingestion of
commercial probiotic supplements during the inter-
vention. With the exception of the probiotic ingestion,
all pregnant mothers and infants were advised not to
change their normal lifestyles, such as food and exer-
cise, during the intervention.
CLINICAL OBSERVATION
At the start of the intervention, each mother com-
pleted a questionnaire about her allergy history,
smoking, and ingestion of fermented milk during
pregnancy, as well as the allergy history of other fam-
ily members of the newborn (e.g., grandfathers,
grandmothers, father, and older siblings), pet keep-
ing, and smokers in the family. The infants were
scheduled for follow-ups until the age of 36 mo. Clini-
cal examination of the infants was performed in ac-
cordance with Japan’s National Schedule for Health
Checks of Infants and Children at 4, 10, 18, and 36
mo of age at health care centers in each municipality
of Wakayama Prefecture. The physicians who per-
formed the physical examination were informed
about the study and were asked to determine
whether the following allergic symptoms were pre-
sent in the infants: eczemaAD, allergic asthma, aller-
gic rhinitis, and allergic conjunctivitis. However, no
detailed information was given to the physician about
the intervention, including the assignment of probi-
otic supplementation, and no physician was directly
involved in the intervention. The primary outcome
measure of the trial was the incidence of eczemaAD
in the infants. The occurrence of eczemaAD, allergic
asthma, allergic rhinitis, and allergic conjunctivitis
was examined in accordance with the Guidelines of
the Japanese Dermatological Association on Eczema
(2005), the Guidelines for the Treatment and Man-
agement of Childhood Asthma in Japan (2005), the
Guidelines for Nasal Allergy Clinics in Japan (2005),
and the Guidelines for the Clinical Management of
Allergic Conjunctival Diseases (2005), respectively
(All the guidelines are written in Japanese). Eczema
AD was diagnosed according to the presence of the
following features: pruritus, typical morphology and
distribution, and a chronic relapsing course.15
ANALYSIS OF FECAL MICROBIOTA BY NEXT-
GENERATION SEQUENCING
Fecal samples were collected from the mothers be-
fore beginning sample intake and at postpartum and
from the infants at the time points of each assessment
using a sampling kit (Techno Suruga Laboratory, Shi-
zuoka, Japan), which enabled the quick stabilization
of DNA and sample processing at room temperature.
DNA was extracted from the fecal samples as de-
scribed previously with some modifications.16 50 μL
of 10% sodium dodecyl sulfate, 500 μL of phenol-
chloroform, and 300 mg of glass beads (diameter, 0.1
mm) were added to 450 μL of fecal suspension. The
mixture was vigorously vortexed for 30 s using a
FastPrepTM FP 100A (Bio 101) at a power level of 5.0.
After centrifugation at 14000× g for 5 min, 400 μL of
supernatant was extracted with phenol-chloroform,
and 250 μL of the supernatant was precipitated with
isopropanol. Inhibitors were removed using a High
Pure PCR Template Preparation Kit (Roche Diagnos-
tics, Switzerland). The purified DNA was suspended
in 200 μL of Tris-EDTA buffer (pH 8.0).
The V6-V8 region of the bacterial 16S rRNA genes
was amplified by PCR using the bacterial universal
primer set, Q-968F-# (5’-CWSWSWWSHTWACGCGA
RGAACCTTACC-3’) and Q-1390R-# (5’-CWSWSWWS
HTTGACGGGCGGTGWGTAC-3’) (# indicates a se-
ries of 128 barcode sequence tags that are underlined
in the sequence).17 The DNA was amplified using the
following program: preheating at 95℃ for 3 min, 20
cycles of denaturation at 95℃ for 15 s, annealing at
54℃ for 30 s, extension at 72℃ for 20 s, and a final
terminal extension at 72℃ for 5 min. The PCR prod-
ucts were purified using a QIAquick PCR Purification
Kit (Qiagen, Valencia, CA, USA) according to the
manufacturer’s protocol. The purified products were
quantified using a NanoDrop ND-1000 micropho-
tometer (NanoDrop Technologies, Wilmington, DE,
USA). Subsequently, equal amounts (100 ng) of the
amplicons from different samples were pooled and
purified before pyrosequencing by ethanol precipita-
tion. The amplicon DNA mixtures were clonally am-
plified by emulsion PCR (emPCR) using a GS FLX Ti-
tanium LV emPCR Kit (Lib-L) v2 according to the
manufacturer’s protocol (454 Life SciencesRoche Di-
agnostics). Beads with amplified DNA were loaded
onto a GS FLX Titanium PicoTiterPlate with dividers
between the separate reaction chambers to accom-
modate two-mixture pools. The amplicon mixture was
applied to the Genome Sequencer FLX454 Titanium
System (454 Life SciencesRoche Diagnostics).
The sequences that passed the quality filters were
analyzed using the QIIME software package.18 They
were sorted into each sample batch with barcode se-
quences. The parameters used in this script were as
follows: l (minimum sequence length) = 400; e (maxi-
mum number of errors in barcode) = 0; reverse
primer mismatches = 2; and a (maximum number of
ambiguous bases) = 3. Potential chimeric sequences
were removed using UCHIME and assigned to opera-
tional taxonomic units (OTUs) using OTUpipe with a
97% threshold of pairwise identity.19 The sequences
were classified taxonomically using the Greengenes
reference database and a confidence threshold of
60%.20 For technical reasons, analysis of the fecal mi-
crobiota was performed using samples from 64 ran-
domly selected mother-infant pairs (probiotic group,
n = 49; control group, n = 15), which consisted of a to-
tal of 256 samples, including those collected from
mothers before intervention and at postpartum and
from infants at 4 and 10 mos of age. The baseline
Bifidobacteria Prevent Eczema in Infants
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Table　2　Background characteristics of mother-infant pairs included in microbiota analyses
Control group (n = 15) Probiotic group (n = 49) P†
Maternal eczema or atopic dermatitis (%) 13.3 28.6 0.318
Family history of allergy (%)‡ 66.7 79.6 0.301
Boy, ratio (%) 53.3 53.1 0.781
Older siblings, ratio (%) 80.0 63.3 0.347
Cesarean section, ratio (%)  0.0 10.2 0.329
Mainly breast-fed, ratio (%) 60.0 63.3 0.939
Pets, ratio (%) 13.3 24.5 0.488
Occurence of infantile eczema/atopic dermatitis
 4 months of age 20.0 12.2 0.426
10 months of age 46.7  6.1 <0.001
†Groups were compared using Fisher’s exact test for categorical variables.
‡Family history including grand fathers, grand mothers, fathers, mothers and siblings of infants.
characteristics of these participants in the probiotic
and control groups are shown in Table 2. Conse-
quently, 735493 sequences were assigned to 256 sam-
ples in which there were 2,873 ± 2,021 (mean ± stan-
dard deviation) reads per sample.
STATISTICAL ANALYSIS
All statistical analyses were performed using SAS sta-
tistical software version 9.1.3 (SAS Institute, NC,
USA). Continuous background data are expressed as
means with standard errors (SD), and categorical
data are expressed as percentages. Differences in
background characteristics between the groups were
compared using Student’s t-test for continuous vari-
ables and Fisher’s exact test for categorical variables.
To assess the effects of the intervention on outcome,
comparisons between groups were conducted using
univariate logistic analyses and are expressed as P
value and odds ratio (OR) with 95%CI. Microbiota
data are expressed as the median and IQR (interquar-
tile range) of the proportion of each bacterial cate-
gory in the microbiota, and the intergroup difference
at each time point was analyzed using the Mann-
Whitney U-test. Correlation was analyzed using
Spearman’s correlation. P < 0.05 was considered sta-
tistically significant.
RESULTS
BASELINE CHARACTERISTICS OF PARTICI-
PANTS AND COMPLIANCE WITH SAMPLE IN-
TAKE
The age ranges of the pregnant mothers were similar
in both groups. No significant differences were found
in the maternal histories for food allergy, allergic
rhinitis, or allergic conjunctivitis of the pregnant
mothers. However, the prevalence rates of eczema
AD (P = 0.023) and with at least one allergy (P =
0.038) were significantly higher in the probiotic
group compared with the placebo group; the preva-
lence of allergic asthma tended to be higher in the
probiotic group (P = 0.057) (Table 1). The prevalence
of a family history of allergy was higher in the probi-
otic group, but this difference was not significant (P =
0.111) (Table 1). No significant differences were ob-
served in the other baseline characteristics between
the two groups. The pregnant women in the probiotic
group received the intervention for 27.3 ± 7.5 d, and
their compliance with probiotic ingestion was 92.0% ±
12.0%. The infants in the probiotic group received the
intervention for 176.3 ± 30.0 d, and their compliance
with probiotic ingestion was 88.0% ± 17.9%. No ad-
verse effects related to probiotic supplementation
were detected in the study subjects.
DEVELOPMENT OF ALLERGIC DISEASES IN IN-
FANTS
Compared with the control group, the prevalence of
eczemaAD was slightly lower at 4 mo of age and sig-
nificantly lower at 10 and 18 mo of age in the probi-
otic group (Table 3). The prevalence of allergic
asthma, allergic rhinitis, and allergic conjunctivitis
was very low at all ages up to 18 mo for both groups,
and there was no significant inter-group difference
(Table 3).
SUBGROUP ANALYSIS OF THE PREVALENCE
OF ECZEMAATOPIC DERMATITIS
When stratified for maternal allergy, the prevalence
of eczemaAD at 10 mo of age in the probiotic group
tended to be lower than that of the control group
when comparing the subgroups with or without ma-
ternal allergy. At 18 mo of age, the prevalence was
significantly lower than that of the control group (P =
0.005) only among the infants of mothers without al-
lergy (Table 4). When stratified by family history of
allergy, the prevalence of eczemaAD in the probiotic
group was significantly decreased compared with the
control group among infants with a family history at
10 mo of age (P = 0.025) and among infants without a
family history at 4 (P = 0.049) and 18 (P = 0.002) mo
of age (Table 4). Among the infants fed primarily for-
mula milk, a reduced prevalence of eczemaAD was
Enomoto T et al.
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Table　3　Occurrence of allergic diseases in infants
Ratio (%)†
P‡ OR (95% CI)‡
Control group Probiotic group
Eczema or atopic dermatitis
 4 months 4/32 (12.5) 12/112 (10.7) 0.755 0.840 (0.268-3.185)
10 months 10/31 (32.3) 10/101 (9.9) 0.007 0.231 (0.084-0.628)
18 months 8/31 (25.8) 9/94 (9.6) 0.033 0.304 (0.105-0.892)
Allergic asthma (%)
 4 months 0/32 (0) 1/111 (0.9) ns n/a
10 months 1/32 (3.2) 2/101 (2.0) ns n/a
18 months 1/31 (3.2) 2/94 (2.1) ns n/a
Allergic rhinitis (%)
 4 months 0/32 (0) 1/111 (0.9) ns n/a
10 months 0/31 (0) 0/101 (0) ns n/a
18 months 0/31 (0) 0/94 (0) ns n/a
Allergic conjunctivitis (%)
 4 months 0/32 (0) 0/111 (0) ns n/a
10 months 0/31 (0) 0/101 (0) ns n/a
18 months 0/31 (0) 0/94 (0) ns n/a
†Number with allergic diseases/total number (percentages).
‡Groups were compared using univariate logistic analyses and expressed as P values and odds ratio (OR) with 95%C.
ns, not signifi cant; n/a, not analyzed.
observed in the probiotic group when compared with
the control group at 10 (P = 0.0005) and 18 (P =
0.040) mo of age (Table 4). No significant difference
between the groups was observed at the other time
points.
FECAL MICROBIOTA COMPOSITION
First, we compared the fecal microbiota composition
of samples from infants with or without eczemaAD
at 4 and 10 mo of age. At 4 mo of age, the proportion
of Actinobacteria was significantly lower in the fecal
microbiota of infants diagnosed with eczemaAD
compared with those without symptoms, whereas
Proteobacteria tended to be higher (Table 5). In addi-
tion to the above differences, a significantly higher
proportion of Firmicutes was found in the fecal micro-
biota of 4-mo-old infants who developed eczemaAD
compared with those without symptoms at 10 mo of
age (Table 5). However, none of these differences
were apparent in the fecal microbiota at 10 mo of age.
Next, we assessed the effect of the probiotic treat-
ment on the fecal microbiota of pregnant mothers
and infants. No significant difference was observed
between the microbiota of mothers before beginning
sample intake, whereas at postpartum, the proportion
of Proteobacteria was significantly lower in the probi-
otic group than in the control group (Table 6). A sig-
nificantly higher proportion of Bacteroidetes was ob-
served in the microbiota of infants in the probiotic
group than in that of the control group at 4 mo of age;
however, no difference in the samples obtained at 10
mo of age was evident (Table 6). Significantly positive
and negative correlations were found in the propor-
tions of Proteobacteria and Firmicutes, respectively,
between mothers at postpartum and infants at 4 mo of
age (Table 7). In addition, significantly negative cor-
relations were found between the proportions of Bac-
teroidetes in mothers and that of Actinobacteria in in-
fants, the proportions of Firmicutes in mothers and
that of Proteobacteria in infants, and the proportions
of Proteobacteria in mothers and that of Bacteroide-
tes in infants, respectively. On the other hand, signifi-
cantly positive correlations were found between the
proportions of Bacteroidetes in mothers and that of
Firmicutes in infants, and the proportions of Fir-
micutes in mothers and that of Actinobacteria in in-
fants, respectively (Table 7).
DISCUSSION
In the present study, we found that prenatal and post-
natal supplementation with a bifidobacterial combina-
tion significantly reduced the risk of developing ec-
zemaAD when compared with a non-supplemented
control group of infants. Because the prevalence of
other allergic diseases such as allergic asthma, aller-
gic rhinitis, and allergic conjunctivitis was very low at
all ages up to 18 mo for both groups, the effect of pro-
biotic supplementation could not be evaluated. This is
the first study to demonstrate the primary prevention
of atopic diseases by probiotic administration in the
Japanese population.
Most studies seeking to prevent eczemaAD in in-
fants have been performed by administering bacteria
to pregnant women and then their infants. In the ma-
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Table　4　Occurrence of eczema/atopic dermatitis in subgroups
Ratio (%)†
P‡ OR (95% CI)‡
Control group Probiotic group
Maternal allergy (at least one allergy)
Yes
 4 months 1/13 (7.7) 6/70 (8.6) 1.000 1.125 (0.17-22.231)
10 months 3/11 (27.3) 5/67 (7.5) 0.080 0.215 (0.043-1.202)
18 months 1/12 (8.3) 6/56 (10.5) 1.000 1.294 (0.193-25.708)
No
 4 months 3/19 (15.8) 6/41 (14.6) 1.000 0.914 (0.212-4.758)
10 months 7/20 (35.0) 5/34 (14.7) 0.101 0.320 (0.081-1.184)
18 months 7/19 (36.8) 2/36 (5.6) 0.005 0.101 (0.014-0.483)
Family allergy history
Yes
 4 months 0/22 (0) 10/91 (11.0) 0.205 n/a (1.22-na)
10 months 8/24 (33.3) 10/85 (11.8) 0.025 0.267 (0.090-0.795)
18 months 4/23 (17.4) 8/72 (11.1) 0.476 0.594 (0.167-2.419)
No
 4 months 4/9 (44.4) 2/21 (9.5) 0.049 0.132 (0.015-0.867)
10 months 2/6 (33.3) 0/14 (0) 0.079 n/a (n/a-n/a)
18 months 4/7 (57.1) 0/20 (0) 0.002 n/a (n/a-n/a)
Nutrition
Mainly breast-fed
 4 months 3/24 (12.5) 11/75 (14.7) 1.000 1.203 (0.337-5.686)
10 months 3/18 (16.7) 7/56 (12.5) 0.698 0.714 (0.174-3.625)
18 months 5/23 (21.7) 7/60 (11.7) 0.299 0.475 (0.134-1.778)
Mainly formula-fed
 4 months 1/8 (12.5) 1/37 (2.7) 0.327 0.194 (0.007-5.300)
10 months 7/13 (53.8) 3/45 (6.7) 0.001 0.061 (0.011-0.280)
18 months 3/8 (37.5) 2/34 (5.9) 0.040 0.104 (0.011-0.770)
†Number with allergic diseases/total number (percentages).
‡Groups were compared using univariate logistic analyses and expressed as P values and odds ratio (OR) with 95%C.
n/a, not analyzed.
jority of cases, a reduced risk of eczema was ob-
served in the infants,3-6 but a few studies found no evi-
dence of reduced incidence.21 Several studies have
administered probiotics to mothers and their infants
who had or did not have a high risk for allergy.3,6,22,23
In addition, although recent works have suggested
that maternal supplementation with probiotics during
pregnancy and breastfeeding may reduce the risk of
eczema in their infants,23,24 prenatal intervention
alone does not affect the risk of eczema in their in-
fants.25 To illustrate the association between back-
ground risk factors and the efficacy of probiotic in-
gestion in the prevention of allergy, we analyzed sub-
groups stratified by maternal allergy, family history of
allergy, or style of nutrition. The results demonstrate
that the preventive effects of probiotic supplementa-
tion on eczemaAD in infants at 10 and 18 mo of age
were potentially maintained in the subgroup without
maternal allergy and in the subgroup without a family
history of allergy (Table 4), suggesting that the pre-
ventive effects of probiotic supplementation may be
better in populations without a history of allergy. In
the subgroup analysis that was stratified by nutrition,
we observed significant differences at 10 and 18 mo
of age among infants who were primarily formula-fed
but not among those who were primarily breast-fed
(Table 4), indicating that supplementation of infant
formula with probiotics may be effective in the pre-
vention of eczemaAD in infants. In the present trial,
the mothers were not given probiotic supplementa-
tion during breastfeeding. Future studies are needed
to evaluate the importance of prenatal and post-natal
supplementation to mothers during breastfeeding or
directly to infants for reducing the risk of eczema in
infants.
Several studies have demonstrated differences in
the gut microbiota between allergic and healthy in-
fants with respect to the frequencies of genera, such
as Bifidobacterium, Bacteroides, Propionibacterium,
Klebsiella, Acinetobacter, Escherichia, Staphylococcus,
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Table　5　Difference in the fecal microbiota composition between infants with and without eczema and atopic dermatitis at 4 and 
10 months of age
Category at 
phylum level
Ages of infants 
assessed
Time of fecal 
sample collection
With disease (n = 9) 
Median (IQR, %)†
Without disease (n = 55) 
Median (IQR, %)† P
‡
Actinobacteria  4 months  4 months 27.98 (4.07-57.67) 55.97 (43.42-74.75) 0.048
10 months 46.38 (19.01-58.82) 48.21 (41.93-58.02) 0.481
10 months  4 months 29.55 (7.64-49.53) 57.31 (43.98-75.96) 0.012
10 months 54.02 (47.62-58.63) 47.27 (35.66-57.72) 0.275
Bacteroidetes  4 months  4 months 0.03 (0-10.39) 4.95 (0.03-17.12) 0.332
10 months 0.36 (0.04-12.69) 8.89 (0.18-15.07) 0.334
10 months  4 months 0.2 (0-9.35) 4.07 (0.02-19.29) 0.253
10 months 7.53 (0.22-14.69) 8.56 (0.08-14.62) 0.760
Firmicutes  4 months  4 months 28.87 (20.62-37.81) 16.16 (8.69-36.23) 0.091
10 months 33.33 (32.86-46.1) 28.61 (22.96-40.46) 0.275
10 months  4 months 27.8 (21.11-53.27) 16.2 (8.63-35.16) 0.042
10 months 30.24 (23.99-33.33) 30.8 (23.12-44.27) 0.336
Proteobacteria  4 months  4 months 8.12 (2.7-31.37) 3.35 (1.57-6.2) 0.062
10 months 2.62 (2.03-3.11) 2.82 (1.35-4.37) 0.505
10 months  4 months 6.26 (4.33-28.49) 3.02 (1.48-6.1) 0.023
10 months 1.66 (0.93-2.62) 2.91 (1.64-4.51) 0.112
Unclassifi ed  4 months  4 months 2.27 (0.63-2.86) 2.05 (1.47-2.5) 0.915
10 months 4.7 (2.29-5.49) 4.45 (3.39-5.12) 0.582
10 months  4 months 2.15 (1.87-2.3) 2.05 (1.32-2.81) 1.000
10 months 4.73 (3.89-5.04) 4.45 (3.14-5.27) 1.000
†Data are expressed as the median with IQR (interquartile range) of the proportion of each bacterial category in the microbiota. The pro-
portions of Fusobacteria and Tenericutes were low and there  were no inter-group difference (data not shown).
‡Inter-group difference at each time point was analyzed using the Mann-Whitney U-test.
and Clostridium.17,26-29 In the present study, we ana-
lyzed the composition of the fecal microbiota in moth-
ers and infants. We observed distinct differences in
the fecal microbiota between allergic infants and their
non-allergic counterparts at 4 mo of age; however,
these differences were not evident in the fecal micro-
biota at 10 mo of age. The major differences were
found in the three predominant phyla: Actinobacteria,
Firmicutes, and Proteobacteria. Allergic children
have less bifidobacteria and more clostridia, and en-
terobacteria than nonallergic children.2,30-33 He et
al.34 have reported that allergic infants have an adult-
type Bifidobacterium flora and that healthy infants
have a typical infant Bifidobacterium flora. Moreover,
compared with healthy infants, allergic Japanese in-
fants have more B. catenulatum group and B. bifidum
at 1 and 6 mo of age, respectively.35 The findings of
these studies indicate the importance of the gut mi-
crobiota composition at an early stage of life in pre-
venting the onset of eczemaAD. Although we have
not analyzed differences at the genus level, those
genera that were reported previously might be pri-
mary candidates for the three phyla that were ob-
served in the present study. Whether the change in
the microbiota is a trigger or a result of a particular
disorder is often controversial; however, our data
suggest that the microbiota present in the early
stages of life may play an important function in regu-
lating the development of AD in infants since the dif-
ference was only observed at early stage (4 mo) but
not at later stage (10 mo).
When the effects of the supplementation of bifido-
bacteria on the composition of the fecal microbiota of
the mothers and infants were assessed, we unexpect-
edly found only limited difference between the probi-
otic and control groups among either mothers or in-
fants; a higher proportion of Bacteroidetes in the mi-
crobiota of infants at 4 mo of age and a lower propor-
tion of Proteobacteria in the microbiota of mothers at
postpartum in the probiotic group compared with the
control group. Previous studies have also reported no
major change in the microbiota composition upon
probiotic administration.36-38 McNulty et al.39 demon-
strated that ingestion of bifidobacteria and lactic acid
bacteria resulted in no significant or only minimal
changes in microbiota configuration, but significant
changes in expression of microbiome-encoded en-
zymes involved in numerous metabolic pathways,
from studies in human and mouse models. Further
studies are needed to confirm whether the fecal mi-
crobiota differs at lower classification levels, such as
at the species level, as well as to evaluate the possible
transcriptional and metabolizing changes in the intes-
tinal environments, in the present study.
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Table　6　Comparison of fecal microbiota composition between the probiotic and control groups
Category at 
phylum level Subjects
Time of fecal 
sample collection
Probiotic group (n = 49) 
Median (IQR, %)†,§
Control group (n = 15) 
Median (IQR, %)†,§ P
‡
Actinobacteria Mother before study 8.87 (7.37-11.84) 6.88 (3.62-9.86) 0.200
postpartum 11.23 (6.82-17.55)* 9.72 (5.3-17.07)** 0.560
Infant  4 months 55.97 (43.16-68.59) 50 (28.78-73.63) 0.560
10 months 47.97 (38.5-57.96) 53.65 (42.14-58.74) 0.770
Bacteroidetes Mother before study 11.81 (8.78-15.15) 11.71 (8.34-17.83) 0.510
postpartum 10.89 (6.54-15.38) 9.09 (5.23-15.61) 0.540
Infant  4 months 7.88 (0.03-21.1) 0.03 (0-8.31) 0.025
10 months 8.23 (0.11-14.26) 11.16 (0.13-14.86) 0.770
Firmicutes Mother before study 72.88 (67.02-79.07) 71.38 (61.54-79.97) 0.570
postpartum 70.18 (65.27-76.32) 71.36 (66.99-80.78) 0.410
Infant  4 months 16.44 (8.81-33.3) 26.72 (11.97-45.55) 0.260
10 months 31.67 (23.06-41.68) 28.28 (24.32-37.55) 0.570
Proteobacteria Mother before study 2.04 (0.89-3.63) 1.73 (0.88-3.47) 0.940
postpartum 1.59 (0.46-2.63)* 2.77 (1.81-4.98)* 0.007
Infant  4 months 3.08 (1.75-6.21) 5.57 (2.55-14.26) 0.230
10 months 2.62 (1.49-4) 3.11 (1.9-5.02) 0.260
Unclassifi ed Mother before study 1.42 (0.28-2.22) 2.01 (0.69-3.66) 0.083
postpartum 0.75 (0.24-1.78) 0.21 (0-0.61)*** 0.009
Infant  4 months 2.05 (1.3-2.86) 2.07 (1.49-2.43) 0.830
10 months 4.45 (3.1-5.49) 4.59 (4.16-4.98) 0.910
†Data are expressed as the median with IQR (interquartile range) of the proportion of each bacteria category in the microbiota. The pro-
portions of Fusobacteria and Tenericutes were low and there were no inter-group or sequential difference (data not shown).
‡Inter-group difference at each time point was analyzed using the Mann-Whitney U-test.
§Intragroup difference in the microbiota of mothers before the study and at postpartum was analyzed using the Wilcoxon t test. 
*p < 0.1; **p < 0.05; ***p < 0.01.
Table　7　Correlations between proportion of each major bacterial category in the microbiota of mothers at postpartum and in-
fants at 4 months
Category at phylum level
Spearman’s r coefficients
Fecal bacteria of infants at 4 months
Actinobacteria Bacteroidetes Firmicutes Proteobacteria Unclassifi ed
Fecal bacteria 
of mothers at 
postpartum
Actinobacteria -0.089 -0.166 0.159 0.200 0.010
Bacteroidetes -0.375** 0.052 0.252* 0.232 0.073
Firmicutes 0.364** 0.012 -0.297* -0.340** -0.048
Proteobacteria -0.028 -0.278* 0.048 0.283* -0.007
Unclassifi ed 0.021 0.029 -0.022 -0.015 0.165
*P < 0.05, **P < 0.01, Spearman’s correlation.
Additionally, we observed significantly increased
proportions of Actinobacteria in the microbiota of
mothers at postpartum compared with their propor-
tions before beginning the study (Table 6) in the pro-
biotic and control groups. The proportion of Proteo-
bacteria decreased in the probiotic group but in-
creased in the control group of mothers at postpar-
tum when compared with their proportions before be-
ginning the study (Table 6). The reason for the
changes in the microbiota in the pregnant mothers
has not been established; however, previous studies
showed that the gut microbiota changes dramatically
during pregnancy, with an expansion of bacterial di-
versity and an overall increase in Proteobacteria and
Actinobacteria.40
We observed significantly positive and negative
correlations in the proportions of Proteobacteria and
Firmicutes, respectively, between mothers at postpar-
tum and infants at 4 mo of age. These results provide
evidence of a possible horizontal influence of the
composition of the microbiota of pregnant mothers
on the development of their infants’ microbiota. Con-
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cerning the reason for negative correlation of Fir-
micutes, it may be an influence of possible interac-
tions among intestinal bacteria in the infants’ micro-
biota, since there were also some positive and nega-
tive correlations between the proportions in mothers
and those in infants for inter-group bacteria. These in-
teractions appear much complicated and need for fur-
ther evaluation.
The mechanism for the efficiency of prenatal inges-
tion of probiotics by mothers in the prevention aller-
gic diseases has not been clearly evaluated, however,
it may not be an effect of solely bacterial transforma-
tion from mothers to infants during delivery. Rautava
et al.24 suggested that besides the possible modulat-
ing effect on the composition of maternal vaginal and
intestinal microbiota, which provide an important
colonizing inoculum to the newborn infant, the
mechanisms of prenatal probiotic effects may also be
more indirect. They have shown that maternal prena-
tal probiotic intervention significantly affects immune
gene expression in the placenta and in the fetal gut in
humans.41
This study had several limitations. At first, this
study was an open trial. We were unable to perform a
placebo-controlled trial due to ethical issues in enroll-
ing participants in a placebo control in this hospital.
However, the physicians who diagnosed the allergic
symptoms were independent of the intervention and
were uninformed about the details of the interven-
tion. Thus, we think that diagnoses were made objec-
tively. Next, the baseline characteristics in the probi-
otic group showed a higher prevalence of allergic his-
tory compared with the control group. This observa-
tion was not surprising because the allocation was
based on the willingness of the participants who had
been informed about the aims of the intervention and
the possible effect of probiotic supplementation. A
family history of allergy is a known risk factor for the
development of allergies in infants.42 Because it is not
easy to administer probiotic samples to infants, it is
likely that the participants with a history of allergy
were more interested in probiotic supplementation in
expectation of its potential benefits. Nevertheless, in
spite of the higher incidence of allergy history in the
probiotic group, the prevalence of eczemaAD was
significantly lower in the probiotic group than in the
control group at 10 and 18 mo of age, suggesting the
potential power of probiotic administration to moth-
ers and their infants for the prevention of eczema in
infants.
In conclusion, our data suggest that the administra-
tion of a bifidobacterial combination to mothers (for 1
mo prior to delivery) and their infants (for 6 mo after
birth) may reduce the risk of eczema development in
the infants. These results indicate that probiotic sup-
plementation to infant formula may be effective in the
prevention of eczemaAD in infants. Our data also
suggest that the composition of the microbiota dur-
ing early infant life may be associated with the devel-
opment of allergic diseases. Some limited changes in
the composition of fecal microbiota of mothers and
infants by the bifidobacterial supplementation were
observed, further study is needed to understand the
mechanism by which probiotics act in the prevention
of allergic disease development. We are currently ex-
ploring the development of allergy in children up to 3
years of age.
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